J&J Voluntarily Recalls Rolaids Products - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

J&J Voluntarily Recalls Rolaids Products


ePT--the Electronic Newsletter of Pharmaceutical Technology

McNeil Consumer Healthcare, a division of McNEIL-PPC, part of Johnson & Johnson (J&J, New Brunswick, NJ) issued a voluntary recall on Dec. 9, 2010, for Rolaid products in the United States and Canada due to reports of possible product contamination. The recall is the latest of several product recalls by J&J’s consumer healthcare business relating to problems in quality control and quality assurance in its manufacturing activities.   

McNeill is voluntarily recalling of lots of Rolaids Extra Strength Softchews, Rolaids Extra Strength plus Gas Softchews, and Rolaids Multi-Symptom plus Anti-Gas Softchews distributed in the United States. McNeil also is voluntarily recalling all lots of Rolaids Ultra Strength SoftChews and Rolaids Ultra Strength SoftChews plus Gas Relief distributed in Canada.

McNeil said it is taking this action following some consumer reports of foreign materials in the product, including metal and wood particles. McNeill said that a company investigation has determined that the materials were potentially introduced into the product during the manufacturing process at a third-party manufacturer. The company also has suspended production of these products and said it will not restart production until corrective actions have been implemented.

See related stories:
A Timeline of J&J/McNeil’s Recent Recall Troubles (PharmTech blog)

FDA Testifies to Congress Regarding J&J Recalls, Quality Concerns  (ePT)

J&J Voluntarily Recalls Certain OTC products (ePT)

J&J Voluntarily Recalls Certain OTC Products Because of Manufacturing Problems (ePT)

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here